At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Double Dummy, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of An H3 Receptor Antagonist (PF-03654746) On Congestion Following A Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis.
In Brief
A Phase 2 clinical trial evaluating Placebo, Allegra, and 2 other interventions for Allergic Rhinitis. Completed, enrolled 21 participants across 1 site.
Detailed Summary
An H3 receptor antagonist should reduce the congestion associated with allergic rhinitis. A nasal allergen challenge will be given to patients to induce rhinitis symptoms and acoustic rhinometry will be used to measure the congestion.
Study Details
Timeline
Interventions
A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
A single oral dose of Allegra-D is dosed to subjects as an active comparator.
A single oral dose of PF-03654746 is the investigational drug being studied.